2010
DOI: 10.1111/j.1468-3083.2009.03527.x
|View full text |Cite
|
Sign up to set email alerts
|

C‐reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy

Abstract: We propose CRP as a useful marker of psoriasis severity that could be used to monitor psoriasis and its treatment, and, together with PASI and elastase, could also be used as a global index of severity.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

19
134
2
10

Year Published

2010
2010
2017
2017

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 119 publications
(165 citation statements)
references
References 39 publications
(57 reference statements)
19
134
2
10
Order By: Relevance
“…The findings of present study correlate well with findings of previous studies -Pereira et al (2004) [5], Coimbra et al (2009) [15], Yiu et al (2011) [16] and Lucy Piper et al (2012) [4].…”
Section: Increased C -Reactive Protein Levelssupporting
confidence: 83%
“…The findings of present study correlate well with findings of previous studies -Pereira et al (2004) [5], Coimbra et al (2009) [15], Yiu et al (2011) [16] and Lucy Piper et al (2012) [4].…”
Section: Increased C -Reactive Protein Levelssupporting
confidence: 83%
“…31 An association between increased CRP levels, neutrophil activation, chronic systemic inflammation and risk for cardiovascular diseases has already been reported in the literature. 32,33 Spesifically NLR and serum CRP levels, which were found to be elevated in CSU patients in the present study, have shown to be prognostic and predictor markers in cardiovascular diseases. What we discuss here is, if the patients with CSU without any systemic, inflammatory or autoimmune diseases might be under the risk of development of cardiovascular diseases in the future.…”
Section: Discussionmentioning
confidence: 77%
“…Since etanercept does not cross BBB it is likely that modulation of circulating inflammatory markers was responsible for the changes (Krishnadas, 2010). While it is possible that the reduction in 5-HTT availability was the result of improvement in clinical symptoms of psoriasis/arthritis, reduction in CRP -a marker of clinical inflammatory activity -was not associated with the reduction in 5-HTT (Beygi et al, 2013;Coimbra et al, 2009;Strober et al, 2008). In addition, clinical response rates to etanercept are around 50% and peak at 4 to 6 months following therapy.…”
Section: Discussionmentioning
confidence: 90%